At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 100 enrolled
Drug / intervention
Hetrombopag +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Hetrombopag in Children and Adolescents With Chronic Primary Immune Thrombocytopenia：a Randomized, Multicenter, Placebo-controlled Trial
In Brief
A Phase 3 clinical trial evaluating Hetrombopag and Placebo for Immune Thrombocytopenia. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the efficacy, safety of Hetrombopag in children with previously treated chronic immune thrombocytopenia who are between 6 and 17 years of age. This is a 2 part study. In part A, patients will receive Hetrombopag for 8 weeks. In part B, all patients will receive Hetrombopag for 24 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartMar 2021
Primary CompletionDec 2024
Study CompletionJun 2025
TodayJul 2026
First PostedFeb 4, 2021
Enrollment StartMar 29, 2021
Primary CompletionDec 31, 2024
Study CompletionJun 17, 2025
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.4 years ago
Interventions
Hetrombopagdrug
Thrombopoietin receptor agonist
Placebodrug
Placebo with no active pharmaceutical ingredient